Dr. Lal PathLabs (NSE:LALPATHLAB) Valuation Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:LALPATHLAB Dr. Lal PathLabs Ltd NSE:LALPATHLAB
93 GF Score
Price ₹1,949.90
GF Value ₹1,735.83
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Dr. Lal PathLabs Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Dr. Lal PathLabs Valuation Rank Related Terms

NSE:LALPATHLAB
93GF Score
Dr. Lal PathLabs Ltd NSE:LALPATHLAB
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Dr. Lal PathLabs (NSE:LALPATHLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Dr. Lal PathLabs stock appears to be overvalued. The current stock price of ₹1,949.90 is trading 12.3% above its estimated GF Value™ of ₹1,735.83. GuruFocus considers Dr. Lal PathLabs to be Modestly Overvalued.

Key valuation signals for NSE:LALPATHLAB:

  • Valuation Rank:
  • GF Value™: ₹1,735.83 vs. price of ₹1,949.90 (12.3% above fair value)
  • GF Score™: 93/100 with 5 warning signs

No single metric tells the full story. See the NSE:LALPATHLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Dr. Lal PathLabs Business Description

Other Exchanges 539524:India
Address 12th Floor, Tower B, SAS Tower, Sector 38, Medicity, Gurugram, HR, IND, 122 001
Dr. Lal PathLabs Ltd is a pathology lab based in India. It is involved in providing diagnostic services and other healthcare tests in the areas of pathology and radiology. The company operates laboratories for carrying out pathological diagnostic services in various branches of biochemistry, hematology, histopathology, microbiology, electrophoresis, immunochemistry, immunology, virology, cytology, and other pathological and radiological investigations. Its diagnostic services assist in preventing, monitoring, and treating diseases and improving health conditions. The company has business operations in India and other countries, of which maximum revenue is generated within India.
93GF Score

Get the complete analysis for NSE:LALPATHLAB

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,949.90
Price
₹1,735.83
GF Value